This Plain Language Summary of Publication article (PLSP) from Future Oncology compared the real-world effectiveness of two prostate cancer treatments – abiraterone and enzalutamide – when used with androgen deprivation therapy (ADT) for metastatic castration-resistant prostate cancer (mCRPC). Using Medicare database information from older U.S. patients, researchers examined survival rates and the influence of factors like age and other health conditions on treatment outcomes. Unlike controlled clinical trials with specially selected patients, this real-world study observed how these treatments performed in everyday medical practice, providing practical insights into their effectiveness in regular healthcare settings.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer’ and was published in Prostate Cancer and Prostate Diseases.

Visit Nature using the link to read the original article.